RESPIRATORY SYNCYTIAL VIRUS (RSV)
Clinical trials for RESPIRATORY SYNCYTIAL VIRUS (RSV) explained in plain language.
Never miss a new study
Get alerted when new RESPIRATORY SYNCYTIAL VIRUS (RSV) trials appear
Sign up with your email to follow new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Pregnant RSV shot shields newborns: major brazil study launches
⭐️ VACCINE ⭐️ Not yet recruitingThis study will check how well the RSVpreF vaccine works when given to pregnant women in Brazil. Researchers will follow about 5,000 babies up to 6 months old who get sick with breathing problems. By comparing vaccinated and unvaccinated mothers, they aim to see if the vaccine pr…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Sponsor: Inova Medical • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 04:37 UTC
-
New RSV vaccine trial aims to protect women from respiratory virus
⭐️ VACCINE ⭐️ Not yet recruitingThis early-stage study tests a new vaccine (MKK900) against respiratory syncytial virus (RSV) in 120 healthy women aged 18-49. The goal is to check if the vaccine is safe and triggers a strong immune response. Participants will be monitored for side effects and their antibody lev…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Phase: PHASE1 • Sponsor: MAXVAX Biotechnology Limited Liability Company • Aim: ⭐️ VACCINE ⭐️
Last updated May 11, 2026 20:47 UTC
-
New pill could speed recovery for babies with RSV
Disease control Not yet recruitingThis study tests an experimental oral drug called zelicapavir in children aged 28 days to 36 months who have RSV. The drug aims to stop the virus from multiplying and help symptoms clear faster. About 150 children will be enrolled, and the study compares the drug to a placebo to …
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Phase: PHASE2 • Sponsor: Enanta Pharmaceuticals, Inc • Aim: Disease control
Last updated May 26, 2026 04:41 UTC
-
New RSV shot for babies enters human testing
Prevention Not yet recruitingThis study tests a new injection called SIBP-A16 in 36 premature and full-term infants under 1 year old to see if it is safe and how the body processes it. The goal is to prevent respiratory syncytial virus (RSV), a common and serious lung infection in babies. The trial is double…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Institute Of Biological Products • Aim: Prevention
Last updated May 22, 2026 14:03 UTC